-
公开(公告)号:US20140378540A1
公开(公告)日:2014-12-25
申请号:US14344628
申请日:2012-09-12
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
IPC分类号: C07D309/10 , C07D493/08
CPC分类号: C07D309/10 , C07D493/08 , C07H7/04
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I的新化合物和治疗或预防一种或多种可通过抑制葡萄糖转运蛋白-2(SGLT-2)调节或归一化的病症或疾病的药物组合物。
-
公开(公告)号:US20140228303A1
公开(公告)日:2014-08-14
申请号:US14126268
申请日:2012-06-13
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
IPC分类号: A61K31/7048 , A61K31/70 , C07H19/01 , C07H7/04
CPC分类号: A61K31/7048 , A61K31/70 , C07D309/10 , C07D401/04 , C07D493/08 , C07H7/04 , C07H9/04 , C07H13/04 , C07H13/12 , C07H15/04 , C07H19/01
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
-
公开(公告)号:US09018249B2
公开(公告)日:2015-04-28
申请号:US14344628
申请日:2012-09-12
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S. Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur Nanda , Sastry V. R. S. Thungathurthi , Nishan Singh , Sudhir Kumar Sharma
IPC分类号: A61K31/352 , C07D311/00 , C07D309/10 , C07D493/08
CPC分类号: C07D309/10 , C07D493/08 , C07H7/04
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I的新化合物和治疗或预防一种或多种可通过抑制葡萄糖转运蛋白-2(SGLT-2)调节或归一化的病症或疾病的药物组合物。
-
公开(公告)号:US08455479B2
公开(公告)日:2013-06-04
申请号:US12863016
申请日:2009-01-23
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
IPC分类号: C07D243/14 , C07D403/06 , C07D413/12 , C07D487/04 , A61K31/551 , A61P3/10
CPC分类号: C07D243/14 , C07D403/06 , C07D413/12 , C07D487/04
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构体,立体异构体,包括R和S异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物以及通过抑制二肽基肽酶IV(DPP-IV)来治疗或预防可被调节或归一化的一种或多种病症的方法。
-
公开(公告)号:US20100311732A1
公开(公告)日:2010-12-09
申请号:US12863016
申请日:2009-01-23
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
IPC分类号: A61K31/5517 , C07D243/14 , C07D487/04 , A61K31/5513 , A61P3/10 , A61P3/06 , A61P9/10 , A61P9/12 , A61P1/00 , A61P1/04 , A61P25/28 , A61P35/00 , A61P35/04 , A61P19/10 , A61P29/00 , A61P15/16 , A61P17/00 , A61P31/18
CPC分类号: C07D243/14 , C07D403/06 , C07D413/12 , C07D487/04
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构体,立体异构体,包括R和S异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物以及通过抑制二肽基肽酶IV(DPP-IV)来治疗或预防可被调节或归一化的一种或多种病症的方法。
-
公开(公告)号:US08906913B2
公开(公告)日:2014-12-09
申请号:US13380744
申请日:2010-06-22
申请人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur , Sandeep Kanwar , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
发明人: Rajesh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur , Sandeep Kanwar , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
IPC分类号: A61K31/5355 , C07D413/10 , C07D209/52 , C07D417/14 , C07D491/08 , C07D221/22 , C07D487/04 , C07D413/14 , C07D409/04 , C07D471/04 , C07D417/10 , C07D401/10
CPC分类号: C07D221/22 , C07D209/52 , C07D401/10 , C07D409/04 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/08
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构体,立体异构体,包括R和S异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构体形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。
-
公开(公告)号:US20120165320A1
公开(公告)日:2012-06-28
申请号:US13380744
申请日:2010-06-22
申请人: Rajseh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur , Sandeep Kanwar , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
发明人: Rajseh Jain , Sanjay Trehan , Jagattaran Das , Gurmeet Kaur , Sandeep Kanwar , Nishan Singh , Gurmeet Kaur Nanda , Sitaram Kumar Magadi , Sudhir Kumar Sharma
IPC分类号: A61K31/422 , C07D413/14 , A61K31/4439 , A61K31/5377 , A61P25/00 , A61K31/403 , C07D417/10 , A61K31/541 , A61K31/551 , A61K31/5513 , C07D413/10 , C07D403/10
CPC分类号: C07D221/22 , C07D209/52 , C07D401/10 , C07D409/04 , C07D413/10 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/08
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构体,立体异构体,包括R和S异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构体形式,立体异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。
-
公开(公告)号:US20130253029A1
公开(公告)日:2013-09-26
申请号:US13876757
申请日:2011-09-27
IPC分类号: C07D209/52 , A61K45/06 , A61K31/403
CPC分类号: C07D209/52 , A61K31/403 , A61K45/06
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法,优选通过调节神经和/或精神病学靶标(GPCR和/或非GPCR) 。
-
公开(公告)号:US09133116B2
公开(公告)日:2015-09-15
申请号:US13876757
申请日:2011-09-27
IPC分类号: C07D209/52 , A61K31/403 , A61K45/06
CPC分类号: C07D209/52 , A61K31/403 , A61K45/06
摘要: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).
摘要翻译: 本发明涉及式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂化物。 本发明还涉及合成式I的新化合物,其药学上可接受的衍生物,互变异构形式,异构体,多晶型物,前药,代谢物,盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法,优选通过调节神经和/或精神病学靶标(GPCR和/或非GPCR) 。
-
-
-
-
-
-
-
-